中科院上海生科院求索讲坛第39期：

本期嘉宾：礼来（中国）研发首席运营官 董海军 博士

本期主题：1） Pharma China R&D Strategy: an Eli Lilly perspective 

               2)   Life and Career

董博士将从世界500强公司“礼来”的角度，谈跨国制药公司在中国的研发战略；并和大家分享关于出国，创业，外资，国有和私人企业等生活和职业选择等。

时间：2012年4月12日（周四）18:30

地点：岳阳路320号生科大楼二楼报告厅

本次讲座及现场礼品由 美国 EPITOMICS公司 友情赞助

董博士简介：

Dr. Dong received his PhD in chemistry from the University of Washington, and MBA from China Europe International Business School. He cofounded two companies and served as their general manager and CEO: Shanghai Jahwa Pharmaceuticals and IMPACT Therapeutics, Inc. At Jahwa, he and his colleagues successfully completed a number of preclinical and clinical developments of generics and modified-release formulations, and received 12 clinical trial and final marketing approvals from the SFDA. At IMPACT, his team discovered and patented several series of novel PARP-1 and Hedgehog pathway inhibitors as oncology medicines. Dr. Dong worked for Roche, both as a senior principal scientist in the US and as head of DMPK and Drug Safety in China, and for Boehringer Ingelheim, as a senior scientist in the US. He has coauthored a number of publications in journals like JACS and DMD, and drug discovery patents. Dr. Dong is one of the “Leading Talents” selected globally by National Nanjing High and New Tech Zone and Nanjing University of Technology, and a winner of “Innovation and Entrepreneurship” by Jiangsu provincial government.